[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines Inc (PRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,198,314
  • Shares Outstanding, K 27,872
  • Annual Sales, $ 0 K
  • Annual Income, $ -303,270 K
  • EBIT $ -326 M
  • EBITDA $ -330 M
  • 60-Month Beta 2.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.56

Options Overview Details

View History
  • Implied Volatility 69.85% (+0.58%)
  • Historical Volatility 66.64%
  • IV Percentile 12%
  • IV Rank 7.28%
  • IV High 177.65% on 07/01/25
  • IV Low 61.39% on 02/19/26
  • Expected Move (DTE 5) 8.67 (2.63%)
  • Put/Call Vol Ratio 0.88
  • Today's Volume 32
  • Volume Avg (30-Day) 263
  • Put/Call OI Ratio 4.35
  • Today's Open Interest 11,124
  • Open Int (30-Day) 10,662
  • Expected Range 321.35 to 338.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-3.79
  • Number of Estimates 8
  • High Estimate $-3.09
  • Low Estimate $-5.83
  • Prior Year $-3.31
  • Growth Rate Est. (year over year) -14.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
310.01 +6.46%
on 05/01/26
353.00 -6.51%
on 05/07/26
+9.80 (+3.06%)
since 04/08/26
3-Month
271.95 +21.36%
on 03/30/26
356.00 -7.30%
on 02/24/26
+10.45 (+3.27%)
since 02/06/26
52-Week
35.21 +837.29%
on 05/28/25
356.00 -7.30%
on 02/24/26
+291.96 (+767.10%)
since 05/08/25

Most Recent Stories

More News
Praxis Precision Medicines Q1 Earnings Call Highlights

Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026 results...

PRAX : 330.02 (-0.98%)
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A...

PRAX : 330.02 (-0.98%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 330.02 (-0.98%)
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 330.02 (-0.98%)
Can Praxis Precision Medicines Finally Prove Its NDA Pipeline Is Worth the Wait?

Barchart Research What to Expect from PRAX Earnings PRAX Generated April 30, 2026 Current Price $318.79 EPS Estimate $$-3.58 Consensus Rating Strong Buy Average Move 8.28% Can Praxis Precision Medicines...

PRAX : 330.02 (-0.98%)
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a...

PRAX : 330.02 (-0.98%)
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026

Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026 Praxis to...

PRAX : 330.02 (-0.98%)
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed...

PRAX : 330.02 (-0.98%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,...

PRAX : 330.02 (-0.98%)
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous...

PRAX : 330.02 (-0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis Precision Medicines Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 354.72
2nd Resistance Point 348.23
1st Resistance Point 339.13
Last Price 330.02
1st Support Level 323.54
2nd Support Level 317.05
3rd Support Level 307.95

See More

52-Week High 356.00
Last Price 330.02
Fibonacci 61.8% 233.46
Fibonacci 50% 195.60
Fibonacci 38.2% 157.75
52-Week Low 35.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.